MiroslawAMazurczakMD

Oncology • Worthington, MN

Medical Oncology, Sanford USD Medical Center

Join to view full profile

Dr. Mazurczak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Mazurczak's full profile

Already have an account?

Office
1018 6th Ave
Worthington, MN 56187
Phone+1 507-343-6100

Fax+1 507-372-3620
Is this information wrong?

Education & Training

Stony Brook Medicine/University HospitalFellowship, Hematology and Medical Oncology, 1995 - 1998
St Luke's University Hospital/Easton HospitalResidency, Internal Medicine, 1992 - 1995
St Luke’s Hospital – Anderson CampusInternship, Transitional Year, 1992 - 1993
Wroclaw Medical UniversityClass of 1988

Certifications & Licensure

SD State Medical License Active through 2025
MN State Medical License 1999 - 2024
PA State Medical License 1993 - 1998

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL Start of enrollment: 2005 Apr 14
Completed
Phase 2
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Start of enrollment: 2005 Mar 01
Completed
Not Applicable
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Start of enrollment: 2006 Aug 01
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer Start of enrollment: 2006 Dec 01
Completed
Phase 3
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Mar 01
Completed
Phase 1, Phase 2
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Start of enrollment: 2007 Dec 01
Active, not recruiting
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2008 May 15
Active, not recruiting
Phase 3
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Feb 29
Active, not recruiting
Phase 3
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Start of enrollment: 2008 Apr 01
Active, not recruiting
Phase 3
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer Start of enrollment: 2008 Jul 30
Completed
Phase 2
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Start of enrollment: 2008 Jun 15
Completed
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Acute Pain Caused by Paclitaxel in Patients With Cancer Start of enrollment: 2009 Feb 01
Completed
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 1, Phase 2
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Start of enrollment: 2008 Dec 01
Completed
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Start of enrollment: 2009 Jul 16
Completed
Phase 2
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary Start of enrollment: 2009 Sep 01
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 15
Terminated
Phase 3
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2009 Nov 01
Active, not recruiting
Phase 3
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Start of enrollment: 2009 Sep 01
Active, not recruiting
Phase 3
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Terminated
Phase 3
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2010 Jan 01
Terminated
Phase 2
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Start of enrollment: 2011 Jan 07
Completed
Phase 2
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery Start of enrollment: 2010 Sep 17
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Start of enrollment: 2011 Jul 01
Completed
Phase 3
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01
Completed
Phase 2
Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations Start of enrollment: 2012 Mar 16
Completed
Phase 2
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer Start of enrollment: 2012 Jul 01
Completed
Phase 2
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Start of enrollment: 2012 Nov 01
Completed
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Start of enrollment: 2013 Sep 09
Terminated
Phase 1
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Dec 13
Active, not recruiting
Phase 3
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Active, not recruiting
Phase 2
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
Active, not recruiting
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Join now to see all

Publications & Presentations

PubMed

13 citations
Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamou...
Steven F Powell, Miroslaw Mazurczak, Elie G Dib, Jonathon S Bleeker, Louis H Geeraerts, Matthew Tinguely, Michele M Lohr, Steven C McGraw, Ashley W Jensen, Christie A ...> ;Investigational New Drugs. 2022 Jun 1
1 citations
Implementation of a standardized approach to borderline resectable pancreatic cancer in a multisite community oncology program
Jonathan Bleeker, Christopher J. Sumey, Steven F. Powell, Preston D. Steen, Michael D. Keppen, Michele Lohr, Thavam Thambi-Pillai, Peter Kurniali, Miroslaw Mazurczak, ...> ;Surgery Open Science. 2020 Jul 29
4 citations
Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study
Steven Francis Powell, Elie G. Dib, Jonathan Bleeker, Michael D. Keppen, Miroslaw Mazurczak, Keely Marie Hack, Mark M. Gitau, Preston D. Steen, Shelby A. Terstriep, Jo...> ;JCO Precision Oncology. 2018 May 11
26 citations
Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance)
Lisa A. Kottschade, Paul J. Novotny, Alan P. Lyss, Miroslaw Mazurczak, Charles L. Loprinzi, Debra L. Barton> ;Supportive Care in Cancer. 2016 Jan 15
13 citations
Phase III double‐blind, placebo‐controlled study of gabapentin for the prevention of delayed chemotherapy‐induced nausea and vomiting in patients receiving highly emet...
Debra L. Barton, Gita Thanarajasingam, Jeff A. Sloan, Brent Diekmann, Jyotsna Fuloria, Lisa A. Kottschade, Alan P. Lyss, Anthony J. Jaslowski, Miroslaw Mazurczak, Scot...> ;Cancer. 2014 Nov 15
12 citations
Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer
Steven R. Alberts, Tiffany M. Yu, Robert J. Behrens, Lindsay A. Renfro, Geetika Srivastava, Gamini S. Soori, Shaker R. Dakhil, Rex B. Mowat, John P. Kuebler, George P....> ;Pharmacoeconomics. 2014 Aug 26
48 citations
Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Head and Neck Radiotherapy With or Without Chemotherapy: A Phase III, ...
James L. Leenstra, Robert C. Miller, Rui Qin, James A. Martenson, Kenneth J. Dornfeld, James D. Bearden, Dev R. Puri, Philip J. Stella, Miroslaw Mazurczak, Marie D. Kl...> ;Journal of Clinical Oncology. 2014 May 20
44 citations
Prospective Multicenter Study of the Impact of Oncotype DX Colon Cancer Assay Results on Treatment Recommendations in Stage II Colon Cancer Patients
Geetika Srivastava, Lindsay A. Renfro, Robert J. Behrens, Margarita Lopatin, Calvin Chao, Gamini S. Soori, Shaker R. Dakhil, Rex B. Mowat, J. Philip Kuebler, George P....> ;The Oncologist. 2014 May 1
10 citations
Verrucous Carcinoma of the Esophagus: A Potential Diagnostic Dilemma
Kabir Ahmed, Gary Timmerman, Robert Meyer, Tara Nikole Miller, Miroslaw A. Mazurczak, Kimberlee C. Tams, Muslim Atiq> ;Case Reports in Gastroenterology. 2013 Sep 1
162 citations
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
Bret Edward Buckley Friday, S. Keith Anderson, Jan C. Buckner, Chunrong Yu, Caterina Giannini, Francois J. Geoffroy, John Schwerkoske, Miroslaw Mazurczak, Howard Gross...> ;Neuro-Oncology. 2012 Feb 1
120 citations
The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial
Lisa A. Kottschade, Jeff A. Sloan, Miroslaw Mazurczak, David B. Johnson, Bronagh P. Murphy, Kendrith M. Rowland, De Anne A. Smith, Alan R. Berg, Philip J. Stella, Char...> ;Supportive Care in Cancer. 2011 Nov 1
78 citations
A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503
Anne M. Traynor, Ju Whei Lee, Gerald Bayer, John M. Tate, Sachdev P. Thomas, Miroslaw Mazurczak, David L. Graham, Jill M. Kolesar, Joan H. Schiller> ;Investigational New Drugs. 2010 Feb 1
The use of vitamin E for prevention of chemotherapy-induced peripheral neuropathy: A phase III double-blind, placebo controlled study-N05C31.
Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy B, Rowland KM, Smith DA, Berg A, Stella PJ, Loprinzi CL> ;J. Clin. Oncol.. 2009-05-20
65 citations
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.
Stephanie L. Hines, Betty A. Mincey, Todor Dentchev, Jeff A. Sloan, Edith A. Perez, David B. Johnson, Paul L. Schaefer, Steve R. Alberts, Heshan Liu, S. P. Kahanic, Mi...> ;Breast Cancer Research and Treatment. 2009 Feb 12
ECOG 1503: A phase II trial of triapine (NSC#663249) with gemcitabine (T/G) as 2nd line treatment of non-small cell lung cancer (NSCLC).
Traynor AM, Levy DE, Bayer GK, Tate JM, Thomas SP, Mazurczak MA, Graham DL, Kolesar JM, Schiller JH> ;J. Clin. Oncol.. 2006-06-20
58 citations
Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial.
Charles L. Loprinzi, Ralph Levitt, Debra L. Barton, Jeff A. Sloan, Pamela J. Atherton, Denise J. Smith, Shaker R. Dakhil, Dennis F. Moore, James E. Krook, Kendrith M. ...> ;Cancer. 2005 Jul 1
17 citations
The therapeutic application of melatonin in supportive care and palliative medicine
Fade Mahmoud, Nabeel Sarhill, Miroslaw A. Mazurczak> ;The American Journal of Hospice & Palliative Care. 2005 Jul 1
Join now to see all

Hospital Affiliations

Sanford USD Medical CenterSioux Falls, South Dakota
Sanford Worthington Medical CenterWorthington, Minnesota
Sanford Canby Medical CenterCanby, Minnesota